Start your patients on Otezla
DISCOVER RESULTS IN
Oral Ulcers Associated
with Behçets Disease^*†

*† The efficacy and safety of Otezla were evaluated in a multicenter, randomized, placebo-controlled phase 3 trial. Adult patients with Behçet’s Disease (BD) with active oral ulcers who were previously treated with at least 1 non-biologic BD medication (N = 207) were randomized 1:1 to Otezla 30 mg twice daily or placebo for 12 weeks after a 5-day titration period. After 12 weeks, all patients received Otezla 30 mg twice daily.^1-3

In the RELIEF™ trial, the efficacy of Otezla was demonstrated using the following endpoints (Otezla, placebo): change from baseline in the pain of oral ulcers as measured by VAS at week 12 (-42.7, -18.7), proportion of subjects achieving oral ulcer complete response (oral ulcer–free) at week 12 (53%, 22%), proportion of subjects achieving oral ulcer complete response (oral ulcer–free) by week 6 and who remained oral ulcer–free for at least 6 additional weeks during the 12-week, placebo-controlled treatment phase (30%, 5%) and the daily average number of oral ulcers during the 12-week placebo-controlled treatment phase (1.5, 2.6).^1,3

The most common adverse reactions (≥10%) were diarrhea, nausea, headache, and upper respiratory tract infection.^1,3